-- 儘管營收承壓，中國太平洋保險（港交所代號：2601，上海證券交易所代號：601601）第一季淨利仍實現成長。 這家總部位於上海的保險巨頭週二晚間向香港聯交所提交的公告顯示，第一季淨利潤年增4%，從96億元增加到100億元。 每股收益從1元人民幣降至0.94元。 營收年減1.2%，從937億元降至925億元。 保險業務收入年增1%，從696億元增加至702億元。 中國太平洋人壽保險業務收入年增2.6%，達到216億元。已收保費較去年同期下降2.8%，從1,196億元降至1,163億元。新增常規保費年增41%，達到189億元。 中國太平洋人壽保險業務新增業務額成長9.6%，達63.7億元。 代理商通路保費成長3.2%，從829億元增加到855億元；而銀行保險業務保費則下滑22%，從268億元降至209億元。 團體通路保費小幅下降1.3%，從94.2億元降至92.9億元。 財產險業務的初始保費收入下滑0.3%，至630億元；營業收入下滑0.2%，至478億元。 週三下午交易時段，中國太平洋人壽保險在香港和上海的股價分別上漲5%和4%。
Related Articles
Equities
RBC Upgrades Tamboran Resources to Outperform From Sector Perform, Raises Price Target to $55 From $38, Keeps Speculative Risk
Tamboran Resources (TBN) has an average rating of buy and mean price target of $57.40 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$TBN
Asia
Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
$HKG:2607$SHA:601607
Mining & Metals
CGI Q2 Adjusted Net Earnings $483.4M, up 0.6% YoY
$GIB-A.TO